-TheWire Science * The Indian government has consistently discouraged compulsory licenses on generic drugs.   * One of the big questions the India government has not answered is why it isn’t using pharma PSUs to produce drugs and vaccines. * Not one member of Indian industry is willing to stand up and fight for compulsory licenses, and for patients, says lawyer Murali Neelakantan. India has played a crucial role in supporting South Africa, as a...

Scientific knowledge has immensely helped in combating the dreadful coronavirus and its spread. Within a record short period of time, scientists (including virologists, epidemiologists, biostatisticians, etc.) and their research outputs helped the commoners to learn more about the SARS-CoV-2 and how it spreads from one individual to the next one. Common people have now come to know how simple techniques and behavioural change like the wearing of N95 masks, maintaining...

-The Indian Express Innovation in vaccine production can have an impact only if it is accessible to all. Patents and access to life-saving drugs has always been an emotive and contentious issue. The right to healthy life is a moral minimum, and to find a rational basis to deny it is deeply offensive to the idea of life itself. At the same time, pharma corporations and institutions claim patents are a just...

-The Times of India NEW DELHI: India has outrightly rejected allegations in a US report about the country being a chief source of counterfeit medicines to the world and said it is an attack on low cost generic drugs — crucial to make healthcare affordable. The ‘Special 301 Report’ by United States Trade Representative (USTR) slammed India and China as leading sources of counterfeit medicines distributed globally with 20% of all pharmaceutical...

-The Times of India NEW DELHI: Around 40% of the essential medicines in India with lowest MRP are priced significantly higher than estimated production costs, an assessment by the World Health Organisation (WHO) shows highlighting the “exorbitant” profiteering by pharmaceutical companies and the scope for lowering prices of drugs. While innovative and newer drugs for cancer, hepatitis C and rare diseases are out of reach of many due to their unaffordable prices,...